Drug Discovery Collaboration for Metabolic Diseases

A joint drug discovery and development partnership in the field of obesity and diabetes has been announced by Evotect OAI (Hamburg, Germany) and DeveloGen (Abingdon, UK).

The partnership creates an integrated venture combining DeveloGen's pipeline of over 200 primary targets and 30 validated targets as well as its know-how in pharmacology, metabolic diseases, and assay development with Evotec OAI's competencies, which range from assay development and screening to medicinal chemistry and drug manufacture. The partners are already cooperating on activities ranging from target validation to lead optimization in a number of programs. A team of about 40 scientists from both companies will soon be engaged on the project. The partners anticipate eventually forming an alliance with a pharmaceutical company that will take responsibility for later-stage development and commercialization.

"By collaborating with a disease-focused biotech company, we are leveraging both parties' complementary skills to rapidly produce what the pharmaceutical industry needs most: potent and promising product candidates to fill clinical pipelines,” said Dr. Timm Jessen, CSO and president of Discovery Programs Division of Evotec OAI.





Related Links:
Evotec OAI
DeveloGen